Clinical trials for Head and neck cancer

84 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT04585750 #2023-504251-27-00
Phase 2 autres tumeurs solides
Locally Advanced Metastatic Metastatic Castration-resistant TP53 1 2 3 or more
KRAS G12C KRAS non G12C Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05706129 #2023-504254-35-00
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC HER2 Negative HR Negative Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT07213817 #2025-522139-33-00
Locally Advanced Metastatic Metastatic Castration-resistant 1
Systemic Treatment-Naive
3 recruiting sites
Ipsen
Phase 1 / Phase 2 Head and neck cancer #NCT06795412 #2025-521828-30-00
Partie 1 Cancer tête et cou
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Squamous cell carcinoma Locally Advanced Metastatic None 1 2 3 or more
Immunotherapy Immunotherapy
3 recruiting sites
Pyxis Oncology, Inc
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Stomach and esophageal cancer Head and neck cancer #NCT07151040 #2024-519639-40-00
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses Squamous cell carcinoma Locally Advanced Metastatic 1 2 3 or more Chemotherapy
Systemic Treatment-Naive
1 recruiting site
One-carbon Therapeutics AB
Phase 1 / Phase 2 Lung cancer Stomach and esophageal cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT06747585 #2024-515459-39-00
NSCLC (Non-Small Cell Lung Cancer) Esophagus Cervical cancer Squamous NSCLC Squamous cell carcinoma Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT05768139 #2023-000442-41
Cohortes autres tumeurs solides
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses Squamous cell carcinoma HR Positive Locally Advanced Metastatic PIK3CA 1 2 3 or more
6 recruiting sites
Eli Lilly et compagnie